Home › Funds › RICE HALL JAMES & ASSOCIATES, LLC › BMRN

RICE HALL JAMES & ASSOCIATES, LLC position in BMRN

BIOMARIN PHARMACEUTICAL INC · Health Care

RICE HALL JAMES & ASSOCIATES, LLC reported holding 376,343 shares of BMRN (BIOMARIN PHARMACEUTICAL INC) in its Q3 2026 13F filing — a position valued at US$22.6M, representing 1.20% of its reported portfolio and ranking #29 among its reported holdings. RICE HALL JAMES & ASSOCIATES, LLC has disclosed BMRN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)376.34K sh
Reported value held$22.58M
Portfolio Weight1.20%
First reportedQ3 2023
Last changeAdd
Updated2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

How RICE HALL JAMES & ASSOCIATES, LLC's BMRN position evolved

RICE HALL JAMES & ASSOCIATES, LLC first disclosed a stake in BMRN in Q3 2023 at 30,867 shares (US$2.7M). The position peaked in Q3 2026 at 376,343 shares, worth US$22.6M. Across 13 filings, RICE HALL JAMES & ASSOCIATES, LLC increased the stake 5 time(s), trimmed it 7 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 376,343 shares valued at US$22.6M — an increase of 128,119 shares quarter over quarter.. Notable position changes include a 1693% increase in Q3 2025 (shares rose 10% over the following quarter), a 137% increase in Q2 2026 (shares rose 5% over the following quarter), a 52% increase in Q3 2026 (shares fell 5% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 30.87K $2.73M New
Q4 2023 29.41K $2.84M Reduce
Q1 2024 28.72K $2.51M Reduce
Q2 2024 20.68K $1.70M Reduce
Q3 2024 10.33K $725.88K Reduce
Q4 2024 5.79K $380.64K Reduce
Q1 2025 5.88K $415.66K Add
Q2 2025 5.77K $317.07K Reduce
Q3 2025 103.42K $5.60M Add
Q4 2025 100.17K $5.95M Reduce
Q1 2026 104.66K $5.91M Add
Q2 2026 248.22K $14.20M Add
Q3 2026 376.34K $22.58M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About BMRN and 13F data

BMRN (BIOMARIN PHARMACEUTICAL INC) is a Health Care company. 26 other funds we track also report a position in BMRN — the largest reported positions include PRIMECAP MANAGEMENT CO/CA/ (US$899.3M), Viking Global Investors (US$435.8M), VIKING GLOBAL INVESTORS LP (US$435.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding BMRN

All BMRN fund holders →

FAQ

How long has RICE HALL JAMES & ASSOCIATES, LLC held BMRN?

RICE HALL JAMES & ASSOCIATES, LLC has disclosed BMRN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is RICE HALL JAMES & ASSOCIATES, LLC's current position in BMRN?

As of Q3 2026, RICE HALL JAMES & ASSOCIATES, LLC holds 376.34K shares of BMRN (BIOMARIN PHARMACEUTICAL INC), valued at $22.58M, representing 1.20% of its reported portfolio and ranking #29.

Has RICE HALL JAMES & ASSOCIATES, LLC been buying or selling BMRN?

In the latest 13F filing (Q3 2026), RICE HALL JAMES & ASSOCIATES, LLC increased its position in BMRN. The position peaked in Q3 2026 at 376.34K shares.

Which other funds hold BMRN?

Other major institutional holders of BMRN include PRIMECAP MANAGEMENT CO/CA/, Viking Global Investors, VIKING GLOBAL INVESTORS LP, among 26 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.